Li Tian-Hao, Qin Xiao-Han, Wang Li-Quan, Qin Cheng, Zhao Bang-Bo, Cao Hong-Tao, Yang Xiao-Ying, Wang Yuan-Yang, Li Ze-Ru, Zhou Xing-Tong, Wang Wei-Bin
Department of Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Heliyon. 2023 Sep 27;9(10):e20464. doi: 10.1016/j.heliyon.2023.e20464. eCollection 2023 Oct.
Armadillo repeat-containing 10 (ARMC10) is involved in the progression of multiple types of tumors. Pancreatic adenocarcinoma (PAAD) is a lethal disease with poor survival and prognosis.
We acquired the data of ARMC10 in PAAD patients from the cancer genome atlas (TCGA) and gene expression omnibus (GEO) datasets and compared the expression level with normal pancreatic tissues. We evaluated the relevance between ARMC10 expression and clinicopathological factors, immune infiltration degree and prognosis in PAAD.
High expression of ARMC10 was relevant to T stage, M stage, pathologic stage, histologic grade, residual tumor, primary therapy outcome (P < 0.05) and related to lower Overall-Survival (OS), Disease-Specific Survival (DSS), and Progression-Free Interval (PFI). Gene set enrichment analysis showed that ARMC10 was related to methylation in neural precursor cells (NPC), G alpha (i) signaling events, APC targets, energy metabolism, potassium channels and IL10 synthesis. The expression level of ARMC10 was positively related to the abundance of T helper cells and negatively to that of plasmacytoid dendritic cells (pDCs). Knocking down of ARMC10 could lead to lower proliferation, invasion, migration ability and colony formation rate of PAAD cells in vitro.
Our research firstly discovered ARMC10 as a novel prognostic biomarker for PAAD patients and played a crucial role in immune regulation in PAAD.
含犰狳重复序列蛋白10(ARMC10)参与多种类型肿瘤的进展。胰腺腺癌(PAAD)是一种致死性疾病,生存率和预后较差。
我们从癌症基因组图谱(TCGA)和基因表达综合数据库(GEO)数据集中获取PAAD患者的ARMC10数据,并将其表达水平与正常胰腺组织进行比较。我们评估了ARMC10表达与PAAD患者临床病理因素、免疫浸润程度及预后之间的相关性。
ARMC10高表达与T分期、M分期、病理分期、组织学分级、残留肿瘤、初始治疗结果(P<0.05)相关,且与较低的总生存期(OS)、疾病特异性生存期(DSS)和无进展生存期(PFI)相关。基因集富集分析表明,ARMC10与神经前体细胞(NPC)中的甲基化、Gα(i)信号事件、APC靶点、能量代谢、钾通道和IL10合成有关。ARMC10的表达水平与辅助性T细胞的丰度呈正相关,与浆细胞样树突状细胞(pDC)的丰度呈负相关。敲低ARMC10可导致体外PAAD细胞的增殖、侵袭、迁移能力及集落形成率降低。
我们的研究首次发现ARMC10是PAAD患者的一种新型预后生物标志物,并在PAAD的免疫调节中发挥关键作用。